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Abstract
Background: Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by
accumulation of lipoproteinaceous material within alveoli, occurring in three clinically distinct
forms: congenital, acquired and secondary. Among the latter, lysinuric protein intolerance (LPI) is
a rare genetic disorder caused by defective transport of cationic amino acids. Whole Lung Lavage
(WLL) is currently the gold standard therapy for severe cases of PAP.
Case presentation: We describe the case of an Italian boy affected by LPI who, by the age of 10,
developed digital clubbing and, by the age of 16, a mild restrictive functional impairment associated
with a high-resolution computed tomography (HRCT) pattern consistent with pulmonary alveolar
proteinosis. After careful assessment, he underwent WLL.
Conclusion: Two years after WLL, the patient has no clinical, radiological or functional evidence
of pulmonary disease recurrence, thus suggesting that WLL may be helpful in the treatment of PAP
secondary to LPI.
Background : pulmonary involvement in LPI
Pulmonary alveolar proteinosis (PAP) is a rare disease
characterized by the accumulation of a lipoproteinaceous,
eosinophilic, periodic acid-Schiff (PAS) positive material
within alveoli [1]. The disease was first described in 1958
[2] and up to 2002 about 410 cases have been reported in
the literature [3]. The clinical course of the disease is vari-
able, ranging from severe respiratory failure to spontane-
ous remission. PAP occurs in three distinct forms:
congenital, acquired and secondary. The congenital form
derives from mutations in the genes encoding surfactant
protein (SP) B or C or the βc chain of the receptor for the
granulocyte-macrophage colonystimulating factor (GM-
CSF). Acquired (or idiopathic) PAP is the most common
form, occurring in previously healthy adults and is nowa-
days considered an autoimmune disease in which circu-
lating anti GM-CSF neutralizing autoantibodies play a
significant role [4]. Secondary PAP is associated with con-
ditions that lead to functional impairment or reduced
numbers of alveolar macrophages, such as some hemato-
logic malignancies, inhalation of inorganic dusts or toxic
fumes, pharmacologic immunosuppression, certain infec-
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tein Intolerance (LPI).
LPI (MIM# 222700) is an inherited autosomal recessive
hyperdibasic aminoaciduria caused by defective cationic
amino acid (CAA; L-arginine, L-lysine, L-ornithine) trans-
port, normally exerted by the y+L system, at the basola-
teral membrane of epithelial cells in the intestine and
kidney [5]. Clinical findings in LPI patients include: vom-
iting, diarrhea, failure to thrive, hepatosplenomegaly,
bone marrow abnormalities, osteoporosis, episodes of
coma, mental retardation, altered immune response,
chronic renal disease and lung involvement, mainly PAP
[6]. LPI is caused by mutations of the solute carrier family
7A member 7 (SLC7A7) gene [7,8]. The SLC7A7 (MIM#
603593) gene encodes the y+LAT-1 protein which is the
light chain subunit of a member of the heterodimeric
amino acid transporters (HATs) family.
LPI is a very rare disease which was first described in 1965
in two infant Finnish siblings [9]. The majority of cases
reported in the literature concern patients from Finland,
where the disease prevalence is about 1 in 60,000 [10].
In 1993, Parto et al [10] reported data from 31 Finnish
patients emphasising that children with LPI are highly
predisposed to develop PAP and that most adult LPI
patients, even though asymptomatic, show radiologic
signs of interstitial lung disease.
In 1993, Kerem et al [11] reported the case of a 11-year-
old Arabic girl affected by LPI with chronic interstitial
lung disease and pulmonary cholesterol granulomas in
lung biopsy (no evidence of PAP was found). The authors
observed that lung involvement in LPI patients may be
either acute (and life threatening) or chronic (as in the
case reported).
In 1992, Fisher et al [12] described the different patho-
logic patterns of endogenous lipid deposition within the
lung, as found in eight pediatric patients with varying pri-
mary disease (one with LPI): endogenous lipoid pneumo-
nia (ELP), PAP, and pulmonary interstitial and intra-
alveolar cholesterol granulomas (PICG) were described,
often coexisting in the same patient. The patient affected
by LPI had two subsequent lung biopsies revealing signs
consistent with ELP, but at autopsy PAP was the most
striking pattern.
In 1993, Di Rocco et al [13] reported data from three Ital-
ian LPI patients with coexisting interstitial lung disease.
The nature of lung involvement was not specified for any
of the patients.
In 1994, Parto et al [14] reported again on the four pedi-
atric patients already mentioned [10] who died in respira-
tory failure, providing more detailed histologic
descriptions. They concluded that PAP and cholesterol
granulomas, the two main histologic findings in the lung
specimens of patients with LPI, could represent different
stages of the same pulmonary reaction, and hypothesized
that the increased amount of CAA in the alveolar lining in
LPI might predispose the patient for PAP development. In
another paper, the same authors [15] reported on the
ultrastructural analysis of lung specimens from these
patients (histologic evidence of PAP in three and PICG in
one). They found that pulmonary macrophages from
these LPI patients with lung involvement contained sig-
nificantly more multilamellar structures than did control
cells and showed electron-dense material containing an
excess of iron. They stated that the increased concentra-
tions of CAA in the alveolar lining might interfere with
phospholipid metabolism (and thus predispose for PAP
[14]).
In 1995, Parenti et al [16] performed a retrospective anal-
ysis in a cohort of nine patients from southern Italy: they
reported that respiratory involvement (evident in chest
radiographs or HRCT scans) was present in five cases, with
histologically proven PAP in one patient, who died at the
age of 11 years.
In 1996, McManus et al [17] reported the necropsy find-
ings from a 21 year old female with LPI, who died from a
rapidly progressive multiple organ failure. The lungs
showed histological PAP.
Since pulmonary involvement represents one of the major
causes of an impaired clinical course and fatal outcome in
LPI, early diagnosis and subsequent monitoring of such
manifestations should be mandatory. In 1996 Santamaria
et al [18] reported the radiological and functional data of
an Italian cohort of nine patients, already described in
[16]. HRCT and perfusion/ventilation scintigraphy
appeared to be the most sensitive methods to detect lung
involvement in LPI, even in patients without clinical and
functional impairment.
In 2004, Santamaria et al [19] reported on the case of an
Italian boy with LPI and PAP. Whole Lung Lavage (WLL)
was performed on two separate occasions, without clini-
cal improvement. The patient, at the age of 3 years, under-
went a hearth-lung transplantation. Eighteen months later
the patient developed a severe Epstein Barr Virus pneumo-
nia and HRCT scans and transbronchial lung biopsy
showed findings consistent with PAP recurrence in the
donor pulmonary graft. On two separate occasions the
patient was retreated with WLL, without any improve-
ment. The patient died 26 months after transplantation.Page 2 of 7
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cutaneous GM-CSF therapy (6 μg/kg per day) was made
and discontinued after respectively 8 and 6 days due to the
emergence of side effects and excessive leucocytosis.
The number of patients affected by LPI described in the
above summary is less than 50 and the number of patients
with a proven diagnosis of PAP is 7. The estimated
number of LPI cases diagnosed worldwide, as of 1994,
was about 80 [15], and according to Simell [6] the
number may rise to over 100. Based on our search of the
literature, the above reported [19] is the only, unsuccess-
ful, case of PAP secondary to LPI treated with WLL. Here
we report on the case of a boy affected by PAP secondary
to LPI, successfully treated with WLL, with sustained and
long standing remission.
Case presentation
The proband was an Italian boy, currently aged 17. At
eight months of age he was diagnosed LPI, with coexisting
glucose-6-phosphate dehydrogenase (G6PD) deficiency
and VII clotting factor deficiency. Interestingly his clinical
case had already beeen reported by other authors [20], but
at that time pulmonary involvement was not indicated.
Development of lung involvement and diagnosis of PAP
Since 1999, the patient has been followed for the develop-
ment of a mild and stable restrictive functional impair-
ment, associated in the following years with development
of digital clubbing; the patient did not complain for the
presence of dyspnoea. On march 2004, the patient
reported atypical abdominal and thoracic pain. A com-
puted tomography (CT) of the abdomen was performed
and resulted negative except for the images including part
of the lower pulmonary lobes, showing areas of ground
glass attenuation with interlobular septa thickening, a pat-
tern strongly suggesting PAP. Routine laboratory tests
were negative. The restrictive ventilatory defect had wors-
ened but respiratory failure was not present; the patient
started reporting episodes of dyspnoea. Steroid therapy
(prednisone 1 mg/kg/die) was started with close surveil-
lance for possible side effects on bone metabolism. Con-
sidering that PAP in LPI pediatric patients is a serious and
possibly fatal complication, despite the absence of respi-
ratory failure the patient was referred to our centre in
Pavia, where WLL is standard procedure for patients with
PAP [21]. In June 2004, the patient was admitted to the
Pavia Hospital. He still presented with annoying thoracic
pain; at physical examination of the chest fine crackles
were present; pulmonary function testing showed a mod-
erate restrictive ventilatory defect (Table 1); respiratory
failure was not present (in room air PaO2 10.3 kPa, PaCO2
5.3 kPa); routine laboratory investigations showed mild
anemia, thrombocytopenia, marked increase in lactate
dehydrogenase; chest HRCT was consistent with the PAP
diagnosis; the bronchoalveolar lavage fluid (BALf) had a
milky appearance and was rich in foamy macrophages
filled with cholesterol crystals in a diffuse background of
granular eosinophilic amorphous material. The diagnosis
of PAP was confirmed based on the HRCT pattern and
BALf characteristics.
WLL treatment
On June 4th, 2004, the patient was treated with WLL in the
intensive care unit. A chest HRCT was performed the day
before the lavage (Figure 1). Before starting the procedure,
the patient underwent a plasma transfusion in order to
correct clotting deficiency. During WLL a nurse assisted
the chest wall percussions, which require particular care in
patients with osteoporosis. The lungs were sequentially
lavaged, adopting the well established technique used at
our centre, already described in detail [21,22]. The WLL
was successufully performed with satisfactory recovery of
outflow fluid (8 L for the left lung, 9 L for the right); no
complications during or after WLL were observed. The
analysis of the outflow fluid confirmed that phospholip-
ids, total protein and SP-A concentration were remarkably
alterated (Table 2).
Two year follow-up
In the following two years the patient has maintained a
satisfactory respiratory status, assessed at regular visits in
the pediatric department. In March 2005, about 9 months
after WLL, he was re-evaluated with complete functional
tests and chest HRCT. Pulmonary function testing showed
a little improvement, as compared with the pre-WLL test
(Table 1); arterial oxygen saturation, assessed with a
pulse-oximeter, was in the normal range (97 %); exercise
testing (modified Bruce protocol) showed normal exercise
tolerance, and was conducted up to stage 4, with a total
distance covered before exercise interruption of 1172 m
(the test was not performed before WLL because of chest
pain reported by the patient). Chest HRCT (Figure 2), in
comparison with the exam performed immediately before
WLL, showed only minimal, isolated, interlobular septa
thickening in the lower portions of the lower lobes; paren-
chymal density was diffusely increased (650–750 Houns-
field Units) in respect to normal values, even in absence
of ground glass attenuation, but consistent with the mild
functional restrictive impairment. In this setting, anti GM-
CSF autoantibodies were tested and resulted negative (less
than 3 μg/mL).
To date, the patient is in good general condition and has
not reported any recurrence of respiratory symptoms. Reg-
ular follow-up visits are still performed in the pediatric
department, with periodic respiratory function tests and
chest X-ray.Page 3 of 7
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To the best of our knowledge, this is the first reported case
of PAP secondary to LPI succesfully treated with WLL. One
case has already been reported [19] where WLL was per-
formed on two separate occasions without any improve-
ment. However, lack of efficacy in this case may be
attributed to post lung transplant complications. It has
also been observed that WLL is the only effective treat-
ment for severe cases of PAP in children [23]. The efficacy
of the procedure in adults is well established [21] and suc-
cessful use of multiple total lung lavages in infants and
paediatric patients with PAP has already been reported
[24]. Taking into account the fact that lung involvement is
a serious and possibly fatal complication in LPI, we
decided to perform a WLL in our patient, even in the
absence of respiratory failure. This decision was also made
in order to prevent further deterioration of his respiratory
condition that would have led to an urgent WLL.
It has been previously observed that there are no data con-
cerning anti GM-CSF autoantibodies in PAP secondary to
LPI [19]. Determination of anti GM-CSF auto-antibodies
in 15 children and 3 neonates affected by PAP revealed
that in most of the children and all of the neonates the
anti GM-CSF titres were not significantly increased [25].
In addition, mutations of surfactant protein B gene and
other known external or syndromic causes of PAP, includ-
ing LPI, were ruled out in this cohort of paediatric
patients. Therefore, this appears to be the first reported
titre of anti-GM-CSF autoantibodies in a patient with PAP
secondary to LPI. The determined level (less than 3 μg/
mL) was negative for the presence of such antibodies as
expected and is consistent with the secondary form of
PAP, in which the anti-GM-CSF auto-antibodies do not
play a role.
Pathogenesis of lung involvement in LPI remains enig-
matic. Various hypotheses have been proposed. A possi-
ble explanation is that increased concentration of CAA in
the alveolar lining might interfere with cell membrane
and surfactant turnover and thus predispose the patient to
the development of ELP, PICG or PAP [14,15], which rep-
resent the forms of endogenous lipid deposition within
the lung that by some are considered to be different stages
of lung involvement in LPI. An alternative hypotheses is
that PAP secondary to LPI might be considered a disorder
of bone marrow derived monocytes. It is well known that
bone marrow abnormalities may be found in LPI patients
(most frequently erythroblastophagocytosis) and it has
been proposed that primarily altered monocytes may dif-
ferentiate into dysfunctional alveolar macrophages [19].
Based on this hypothesis, bone marrow tranplantation
could be beneficial in LPI complicated by PAP [19].
Recently, it has been found that nitrate levels are increased
in the plasma of patients with LPI: the Authors hypothe-
sized that the increased nitric oxide production could play
a role in the pathogenesis of poorly understood condi-
tions associated with LPI, such as PAP [26].
Uncertainities regarding the pathogenesis of the disease
have severely limited the aetiologic treatment of PAP in
LPI. There is no evidence on the effectiveness of GM-CSF
replacement for this condition: furthermore, it does not
seem that GM-CSF signalling is impaired in PAP compli-
cating LPI, thus suggesting a lack of rationale for substitu-
tive treatment. Bone marrow transplantation is an
intriguing therapeutic option but, to date, there are no
reported cases on its efficacy in PAP secondary to LPI and
a better understanding of bone marrow abnormalities in
LPI is needed. WLL, which provides removal of the accu-
mulated material from the alveolar spaces, is thus an effec-
tive and safe procedure [23,24]. Our case demonstrates
that, since PAP in LPI is a life-threatening complication,
WLL should be accurately evaluated in all patients with
LPI and severe lung involvement. Further studies are
needed to ascertain if WLL is a therapeutic option in
patients who have mild respiratory impairment, or show
a trend for progressive deterioration of lung function.
Table 1: Pulmonary function testing before and 9 months after WLL
BEFORE WLL 9 MONTHS AFTER WLL
Value % predicted Value % predicted
VC 1,09 L 44 1,37 L 51
FRC 0,94 L 70 1,29 L 86
RV 0,49 L 79 0,69 L 103
TLC 1,58 L 55 2,06 L 65
FEV1 0,94 L/s 42 1,06 L/s 44
FEV1/VC 86,24% 102 77,37% 92
RV/TLC 31,01% 151 33,5% 163
Pulmonary function parameters, measured one day before and about 9 months after WLL; mild restrictive impairment is present, with a slight 
improvement after the procedure. VC, vital capacity; FRC, functional residual capacity; RV, residual volume; TLC, total lung capacity; FEV1, forced 
expiratory volume in 1 second.Page 4 of 7
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Table 2: Proteins, phospholipids and SP-A concentrations in WLL outflow fluid.
Total proteins (μg/mL) Phospholipids (μg/mL) SP-A (μg/mL)
Right lung 8,500 150 202
Left lung 6,500 80 41
Controls (mean ± SD) 171 ± 74 46 ± 27 1 ± 1
Concentrations of total proteins, phospholipids and SP-A were measured in the outflow fluid after lavage of both lungs and were found to be 
markedly increased with respect to control levels.
Chest HRCT performed 1 day before WLLFigure 1
Chest HRCT performed 1 day before WLL. Areas of ground glass attenuation with concomitant interlobular septa thick-
ening are evident, alternated with areas of normal lung (crazy paving pattern).
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